A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Last updated: July 30, 2026
Sponsor: Ocugen
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

Macular Degeneration

Geographic Atrophy

Myopic Macular Degeneration

Treatment

OCU410ST

OCU410ST

Clinical Study ID

NCT05956626
OCU410ST-101/301
OCU410ST-101
  • Ages > 5
  • All Genders

Study Summary

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects).

Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.

OCU410ST Phase 1- Retinal Structure and Visual Function Data Results

  • Safety: Favorable safety and tolerability profile No SAE deemed related to OCU410ST including intraocular inflammation, exudation, endophthalmitis, anterior ischemic optic neuropathy (AIONs) or vasculitis.

  • Primary Endpoint: Structural Improvement Atrophic lesions grew slower by 48% at 12M in evaluable treated eyes when compared to untreated eyes

  • Secondary Endpoint: Visual Function (BCVA) 100% evaluable treated eyes demonstrated stabilization or improvement when compared to untreated eyes in visual function

OCU410ST Phase 1- Structural and Functional Outcomes at 12M Data Results

  • The GARDian3 clinical trial for ABCA4- related retinopathies including Stargardt disease builds upon encouraging results and positive data from the Phase 1 GARDian trial, which demonstrated 48% slower lesion growth at 12-month follow-up in evaluable treated eyes compared to untreated eyes

  • Additionally, evaluable treated eyes showed a statistically significant (p=0.031) and clinically meaningful improvement of nearly 2-line/9-letter gain in best corrected visual acuity (BCVA) at 12-month follow-up when compared to untreated eyes.

Eligibility Criteria

Inclusion

Phase 2/3 Inclusion Criteria (applicable for both adult and pediatric subjects):

  1. Males or females aged ≥5 years at the time of consent.

  2. Subjects who have confirmed clinical and CLIA certified or equivalent genetic diagnosis of Stargardt disease (including ABCA4 related retinopathies).

  3. Adult subjects who have BCVA of 75 letters or less in the study eye (20/32 Snellen equivalent) and Pediatric subjects who have a BCVA of 35 letters or better in the study eye (20/200 Snellen equivalent).

  4. The study eye should have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns, and total lesion size must add to less than or equal to ≤ 18 mm^2 (approximately 7-disc areas).

  5. Have detectable outer nuclear layer (ONL) in the macular region

Phase 2/3 Exclusion Criteria (applicable for both adult and pediatric subjects):

  1. Participation in ongoing antiretroviral therapy treatment.

  2. Participation in any investigational therapy study or receipt of investigational treatment within 60 days prior to screening or 5 half-lives (whichever is longer).

Any ophthalmic history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, intravitreal or subretinal injections, or participation in an Alkeus ALK-001 study within the past 6 months.

  1. Macular atrophy secondary to any disease other than Stargardt Disease (STGD).

  2. Presence of genetic mutations that mimic Stargardt Disease like ELOVL4, or PROM1.

  3. Contraindication to subretinal injection or use of anesthesia (local and/or general).

Phase 1 was a multicenter, open-label, dose-ranging/dose escalation study. Enrollment is complete for Phase 1

Study Design

Total Participants: 51
Treatment Group(s): 2
Primary Treatment: OCU410ST
Phase: 2/3
Study Start date:
August 25, 2023
Estimated Completion Date:
September 28, 2026

Study Description

Name of Investigational Product: OCU410ST Name of Active Ingredient: Adeno-associated viral vector 5 human RORA (AAV5-hRORA)

Title of Study: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE

Study Center(s): Approximately fifteen study centers in the US.

Background: Stargardt disease is an eye disease that causes vision loss in children and young adults. It is an inherited disease caused by faulty genes that cause buildup of fat deposits in the eye. Currently, there is no approved treatment available for Stargardt disease.

OCU410ST Product Information:

OCU410ST is an Adeno-Associated Virus serotype 5 containing human RORA for the treatment of Stargardt disease. Dysregulation in lipid metabolism, oxidative stress, and anti-inflammatory mechanisms are critical for pathogenesis and progression of Stargardt disease. The role of hRORA in regulating these gene pathways strongly suggests OCU410ST could restore homeostasis in the eye and thereby serve as a therapeutic candidate for Stargardt disease.

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study.

A total of fifty-one (51) subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects).

Treatment group: 34 subjects. Subjects will receive a single subretinal injection of 200 µL OCU410ST in concentration of 1.5×10E11 vg/mL.

Control group: 17 subjects. Subjects who are enrolled in the untreated control group of the study will not receive any treatment. They will be followed according to the same treatment schedule as the treated subjects.

Note: Data will be collected for the untreated eye at Screening, 4-month, 8-month, 12-month, four (4) long-term safety follow-up visits, and early termination visit (if applicable).

Data will be collected for the treated eye at Screening, treatment Day 1, Day 2, Day 15, 4-month, 8-month, 12-month, four (4) long-term safety follow-up visits, and early termination visit (if applicable).

Enrollment in the Phase 1 study is complete. Phase 1 enrolled a total of nine subjects in low, medium and high dose cohorts.

Low Dose Cohort (3.75×10E10 vg/mL):

Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in low dose concentration (3.75×10E10 vg/mL).

Medium Dose Cohort (7.5×10E10 vg/mL):

Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in medium dose concentration (7.5×10E10 vg/mL).

High Dose Cohort (2.25×10E11 vg/mL):

Three (3) Subjects received a single subretinal injection of 200 µL OCU410ST in high dose concentration (2.25×10E11 vg/mL).

Connect with a study center

  • Associated Retina Consultants

    Phoenix, Arizona 85020
    United States

    Site Not Available

  • Retinal Consultants Medical Group

    Sacramento, California 95825
    United States

    Site Not Available

  • Vitreo Retinal Associates, P.A.

    Gainesville, Florida 32607
    United States

    Site Not Available

  • Bascom Palmer Eye Institute

    Miami, Florida 33136
    United States

    Site Not Available

  • Advanced Research, LLC

    Pompano Beach, Florida 33064
    United States

    Site Not Available

  • Retina Partners Midwest, P.C.

    Carmel, Indiana 46032
    United States

    Site Not Available

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • Mississippi Retina Associates

    Jackson, Mississippi 39202
    United States

    Site Not Available

  • The Retina Institute

    St Louis, Missouri 63128
    United States

    Site Not Available

  • Duke Eye Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Erie Retina Research, LLC

    Erie, Pennsylvania 16505
    United States

    Site Not Available

  • Retina Consultants of Texas

    Bellaire, Texas 77401
    United States

    Site Not Available

  • Retina Foundation of the Southwest

    Dallas, Texas 75231
    United States

    Site Not Available

  • Valley Retina Institute

    McAllen, Texas 78503
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.